Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 01:16am CEST

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
03/24 NOVARTIS : Global Haloperidol Market 2017 - Sandoz, Mylan, Teva, Fresenius Kabi
03/24 NOVARTIS : $11,970 Federal Contract Awarded to Alcon Laboratories
03/24 PURETECH HEALTH : Inks Deal With Novartis To Develop Ageing Disorder Therapies
03/23 NOVARTIS : Lupin receives FDA approval for generic TOBI inhalation solution
03/23 NOVARTIS : Global Alprazolam Market 2017 - Endo, Mylan, Sandoz, Actavis, Apotex
03/23 NOVARTIS : Kisqali® ribociclib, LEE011 receives FDA approval as first-line treat..
03/23 OTSUKA : Ribociclib (LEE011) Receives Regulatory Approval in U.S. as a First-Lin..
03/23 NOVARTIS : Serelaxin Setback Puts Focus On Entresto
03/23 NOVARTIS : Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multi..
03/22 Global Inhalation & Nasal Spray Generic Drugs Market- Teva, Allergan PLC, Cip..
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/24 FDA Decision For Dupixent As Novartis Drives Its CAR-T
03/24 Novartis licenses two anti-aging programs to PureTech Health
03/23 Discussing The Evolving AML Landscape With A Key Opinion Leader
03/23 Pharma Development Budgets Grow As Roche Remains A Believer
03/22 Serelaxin Setback Puts Focus On Entresto
Advertisement
Financials ($)
Sales 2017 48 428 M
EBIT 2017 11 232 M
Net income 2017 7 504 M
Debt 2017 15 034 M
Yield 2017 3,79%
P/E ratio 2017 22,58
P/E ratio 2018 19,96
EV / Sales 2017 4,34x
EV / Sales 2018 4,13x
Capitalization 195 096 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 80,1 $
Spread / Average Target 7,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-0.94%195 096
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
MERCK & CO., INC.7.32%173 465
SANOFI7.76%115 582
More Results